寻找合适剂量:N-甲基-D-天冬氨酸受体调节治疗精神分裂症认知与可塑性缺陷及药效学靶点结合的作用
综述回顾了针对精神分裂症相关认知障碍(CIAS)的NMDAR调节剂临床试验,涵盖D-丝氨酸、D-环丝氨酸、美金刚、甘氨酸及第一代甘氨酸转运抑制剂等,并提及iclepertin和luvadaxistat等新近阳性研究及非侵入性脑刺激。作者强调在治疗开发早期纳入药效学靶点结合生物标志物(如失匹配负波、听觉稳态、时频事件相关电位)有助于预测3期成败。
要点
- CIAS及学习可塑性缺陷是精神分裂症残疾的主要原因,目前无FDA批准的治疗。
- 多种NMDAR调节剂在小型研究中显示希望,但在2/3期试验中失败。
- 早期纳入药效学靶点结合生物标志物可能预测3期试验的成功或失败。
核心结论
- 综述强调在CIAS治疗开发早期纳入药效学靶点结合生物标志物的重要性,以帮助预测化合物在3期试验中的成败。
研究设计与样本
- 综述回顾了已发表的针对CIAS的NMDAR调节剂治疗临床试验,涵盖单独使用及与可塑性/学习范式联合使用的新型NMDAR调节治疗。
主要发现
- 多种NMDAR调节剂(包括D-丝氨酸、D-环丝氨酸、美金刚、甘氨酸及第一代甘氨酸转运抑制剂如肌氨酸和bitopertin)在小型研究中显示初始希望,但在2/3期试验中失败。
- 新近阳性研究包括新型甘氨酸转运抑制剂iclepertin和增加脑内D-丝氨酸水平的D-氨基酸氧化酶抑制剂luvadaxistat。
- 间接非侵入性脑刺激NMDAR调节治疗也被纳入讨论。
关键数值与推荐
- 药效学靶点结合生物标志物示例包括失匹配负波、听觉稳态和时频事件相关电位方法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cognitive impairment associated with schizophrenia (CIAS) and related deficits in learning (plasticity) are among the leading causes of disability in schizophrenia. Despite this, there are no Food and Drug Administration-approved treatments for CIAS, and the development of treatments has been limited by numerous phase 2/3 failures of compounds that showed initial promise in small-scale studies. NMDA-type glutamate receptors (NMDARs) have been proposed to play an important role in schizophrenia; moreover, the NMDAR has a well-characterized role in cognition, learning, and neuroplasticity. We review previously published clinical trials in CIAS that focused on NMDAR modulator treatments, focusing on published and recent developments of the use of novel NMDAR-modulating treatments for CIAS both alone and combined with plasticity/learning paradigms to enhance learning. We use this discussion of previous studies to highlight the importance of incorporating pharmacodynamic target engagement biomarkers early in treatment development, which can help predict which compounds will succeed or fail in phase 3. A range of direct and indirect NMDAR modulators are covered, including D-serine, D-cycloserine, memantine, and glycine and first-generation glycine transport inhibitors (e.g., sarcosine and bitopertin), as well as recent positive studies of iclepertin, a novel glycine transport inhibitor, and luvadaxistat, a D-amino acid oxidase inhibitor that increases brain D-serine levels, and indirect noninvasive brain stimulation NMDAR-modulating treatments. Several examples of successful use of pharmacodynamic target engagement biomarkers for dose/drug discovery are emphasized, including the mismatch negativity, auditory steady state, and time-frequency event-related potential approaches.
引用
- Sehatpour P, Kantrowitz JT. Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement. Biol Psychiatry. 2024. PMID: 39218136. doi:10.1016/j.biopsych.2024.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。